Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

RU58841 is discussed as a hair loss treatment, with users considering lower doses like 2.5% to reduce costs. Some users suggest that if already blocking DHT, lower doses might still be effective unless there's high sensitivity to DHT.

The user experienced improved self-confidence and hair regrowth using finasteride, minoxidil, and dermarolling. Visible results were noted after about three months, with microneedling done once a week.

There is no new information on pp405, with data collection expected to finish by the end of 2025. Users are discussing the timeline for data analysis and completion of Pelage Pharmaceuticals' phase 2 study.

The user is using a combination of oral Dutasteride and Minoxidil, and a topical formula with Finasteride, Minoxidil, and Hydrocortisone, along with rosemary oil, coconut oil, ginseng, and a derma roller. They are also using LLLT therapy and are questioning the timing of the laser cap session in relation to the topical application.

RU58841 slowed hair loss for a DUPA sufferer after other treatments like finasteride, dutasteride, and minoxidil failed. Some users reported side effects with RU58841, while others did not experience any.

PP405 may induce new hair growth but cannot revive completely dead follicles, and its effectiveness on hairlines is uncertain. It is expected to be available by mid-2028, but users are advised to manage expectations and consider using other treatments like minoxidil and finasteride.

The user experienced hair shedding after increasing minoxidil from 5% to 7% with latanoprost, possibly causing telogen effluvium. They are on HRT with Lupron, Estradiol, and Raloxifene, and are concerned about the shedding's duration.

PP405 is a new hair loss treatment that may outperform minoxidil and finasteride by growing thick hair in bald areas within four weeks. Its release is expected around 2028, but concerns about its long-term efficacy and cost remain.

RU58841 lacks FDA approval due to financial and safety concerns, including potential cardiological side effects. The company abandoned further research, and users report adverse effects like heart palpitations and gynecomastia.

Triple Hair Inc. developed a new topical treatment, TH07, combining Finasteride, Latanoprost, and Minoxidil for androgenic alopecia. Users discussed its effectiveness compared to other treatments and shared their own product combinations.

Scientists at UCLA have developed a promising treatment for male pattern baldness using a molecule called PP405, which can potentially stimulate dormant hair follicles. Initial trials showed significant results within a week, but larger clinical trials are needed to confirm its efficacy and safety.

Amplifica raised $26 million to advance its injectable treatments for hair growth. The funding will support the clinical development of their novel therapies.

RU58841's effectiveness from rudirect is questioned. Users discuss experiences with RU58841, Minoxidil, and finasteride for hair loss treatment.

Using topical tretinoin may enhance the effectiveness of minoxidil for hair growth, with some users reporting improved results. A premixed formula of minoxidil and tretinoin is available and has shown better outcomes for some individuals.

People are discussing their reactions if PP405 fails in phase 3 trials, with some expressing skepticism and others holding onto hope for future treatments like GT20029 and Breezula. Many mention continuing with existing treatments like minoxidil and finasteride, while others express disappointment and consider alternative solutions.

Making a hair solution using RU58841 from raw powder. Users humorously compare the process to a science experiment.

A user is using Minoxidil, finasteride, saw palmetto, and Minimalist RCP serum to address hair thinning, with some success but concerns about the long-term benefits of Minimalist. They plan to continue Minoxidil and finasteride for another year before considering a hair transplant.

The user has been using topical minoxidil and dermarolling for hair regrowth but is hesitant to start finasteride due to potential side effects. Many suggest adding finasteride for better results in addressing DHT-related hair loss.

The user is experiencing diffuse androgenic alopecia and is trying various treatments, including 5mg finasteride, loniten, and Formula 82D, which contains dutasteride, a steroid, and tretinoin. They report potential regrowth with Formula 82D, despite previous treatments being ineffective.

PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.

A 17-year-old shared progress pictures after using RU58841 and Minoxidil for 2 months, showing significant hair regrowth. Another user commented on the impressive results achieved in a short time.

DHT negatively affects scalp hair while promoting body hair growth, causing frustration due to the lack of permanent solutions for baldness. Users discuss treatments like finasteride and potential future solutions like CRISPR technology.

PP405 is considered a potential new treatment for hair loss, compared to finasteride and minoxidil. There is skepticism about its effectiveness in humans, with anticipation for more information from an upcoming conference.

The conversation is about the difficulty of applying both pyril and min/fin to treat hair loss twice daily and whether combining them yields positive results.

The conversation is about using Xeljanz for hair regrowth in individuals with LPP. The user is seeking experiences and expectations from others who have tried this treatment.

A user is considering switching to a topical treatment containing finasteride, minoxidil, and tretinoin, instead of their current regimen of oral finasteride and oral minoxidil. They are unsure whether to try the new topical or continue with their current treatment.

PP405 is considered a promising potential cure for hair loss, with phase 2 trial results expected in February 2025. Hair cloning is also discussed as a potential ultimate solution, despite significant scientific challenges.

Laritelle shampoo is questioned for its effectiveness in reducing hair loss and rejuvenating hair follicles. A user dismisses it as ineffective.

PP405 is likely a scam, with concerns about its legitimacy and safety, as it may cause unintended tissue growth. Users suggest sticking to known treatments like finasteride and minoxidil.

User creates 0.1% topical finasteride solution using Alfatradiol Avixis base. Seeks help to ensure alfatradiol base dissolves finasteride.